Anti‐VEGF vs control
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review
- Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes onlyRR 0.17 [0.01, 4.24]6 studies · 2667 participantsModerate